Emtricitabine

• CAT Number: A000770
• CAS Number: 143491-57-0
• Molecular Formula: C8H10FN3O3S
• Molecular Weight: 247.244
• Purity: ≥95%
• Synonyms: 143491-57-0; Emtriva; Coviracil; Racivir; (-)-FTC
• Target: Reverse Transcriptase
• Solubility: >10.4mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
• InChI: InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1
• InChIKey: XQSPYNMVSIKCOC-NTSWFWBYSA-N
• SMILES: C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F

Emtricitabine is a nucleoside analogue which inhibits the reverse nucleoside transcriptase enzyme. Structurally this antiviral agent is similar to Lamivudine. This agent is effective at targeting HIV and HBV viruses since these viruses replicate in a reverse transcriptase manner. Studies indicate that the structure of Emtricitabine, specifically the unnatural β-L structural configuration produce greater antiviral effects in vitro on HIV and HBV than other antiviral agents.

Reference

1: Taramasso L, Riccardi N, Del Puente F, Bruzzone B, Ripamonti D, D/’ambrosio B,
Viscoli C, Di Biagio A. Tenofovir disoproxil fumarate/emtricitabine fits for all
as appropriate HIV-1 preexposure prophylaxis? AIDS Res Hum Retroviruses. 2017 Nov
22. doi: 10.1089/AID.2017.0112. [Epub ahead of print] PubMed PMID: 29166777.

2: Gianotti N, Poli A, Nozza S, Galli L, Galizzi N, Ripa M, Merli M, Carbone A,
Spagnuolo V, Lazzarin A, Castagna A. Durability of switch regimens based on
rilpivirine or on integrase inhibitors, both in association with tenofovir and
emtricitabine, in HIV-infected, virologically suppressed patients. BMC Infect
Dis. 2017 Nov 16;17(1):723. doi: 10.1186/s12879-017-2831-9. PubMed PMID:
29145807; PubMed Central PMCID: PMC5691866.

3: Institute for Quality and Efficiency in Health Care. Elvitegravir / Cobicistat
/ Emtricitabine / Tenofovir Alafenamide — Addendum to Commission A15-61
[Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care
(IQWiG); 2016 May 27. Available from http://www.ncbi.nlm.nih.gov/books/NBK458451/
PubMed PMID: 29144710.

4: Institute for Quality and Efficiency in Health Care. Elvitegravir / Cobicistat
/ Emtricitabine / Tenofovir Alafenamide — Benefit Assessment According to §35a
Social Code Book V [Internet]. Cologne, Germany: Institute for Quality and
Efficiency in Health Care (IQWiG); 2016 Mar 30. Available from
http://www.ncbi.nlm.nih.gov/books/NBK458440/
PubMed PMID: 29144685.

5: Carballo-Diéguez A, Giguere R, Dolezal C, Leu CS, Balán IC, Brown W 3rd, Rael
C, Richardson BA, Piper JM, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales
P, Holtz TH, Liu A, Mayer KH, Zorrilla CD, Lama JR, McGowan I, Cranston RD;
MTN-017 Protocol Team. Preference of Oral Tenofovir Disoproxil
Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens
for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in
Receptive Anal Intercourse with Men. AIDS Behav. 2017 Dec;21(12):3336-3345. doi:
10.1007/s10461-017-1969-1. PubMed PMID: 29119473.

6: Nicol MR, Brewers LM, Kashuba AD, Sykes C. The role of menopause in tenofovir
diphosphate and emtricitabine triphosphate concentrations in cervical tissue.
AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001678. [Epub ahead of print] PubMed
PMID: 29112071.

7: Schauer AP, Sykes C, Cottrell ML, Prince H, Kashuba ADM. Validation of an
LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of
tenofovir, emtricitabine, and lamivudine in dried blood spots. J Pharm Biomed
Anal. 2017 Oct 31;149:40-45. doi: 10.1016/j.jpba.2017.10.030. [Epub ahead of
print] PubMed PMID: 29100029.

8: Harris M, Ganase B, Watson B, Harrigan PR, Montaner JSG, Hull MW. HIV
treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir
disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study. AIDS Res
Ther. 2017 Nov 2;14(1):59. doi: 10.1186/s12981-017-0185-4. PubMed PMID: 29096670;
PubMed Central PMCID: PMC5669010.

9: Inciarte A, Leal L, González E, León A, Lucero C, Mallolas J, Torres B, Laguno
M, Rojas J, Martínez-Rebollar M, González-Cordón A, Cruceta A, Arnaiz JA, Gatell
JM, García F; STRIBPEP Study Group. Tenofovir disoproxil fumarate/emtricitabine
plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a
single-tablet regimen for HIV post-exposure prophylaxis. J Antimicrob Chemother.
2017 Oct 1;72(10):2857-2861. doi: 10.1093/jac/dkx246. PubMed PMID: 29091217.

10: Aloysius I, Savage A, Zdravkov J, Korologou-Linden R, Hill A, Smith R,
Houghton-Price V, Boffito M, Nwokolo N. InterPrEP. Internet-based pre-exposure
prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of
outcomes in 641 patients. J Virus Erad. 2017 Oct 1;3(4):218-222. PubMed PMID:
29057086; PubMed Central PMCID: PMC5632549.